Journal: Journal of Ovarian Research

Article Title: Atractylenolide III mitigates polycystic ovary syndrome by activating FDX1-mediated proliferation of ovarian granulocyte cells via PI3K/AKT/mTOR

doi: 10.1186/s13048-025-01941-7

Figure Lengend Snippet: ATL-III attenuates DHEA-induced mouse PCOS phenotypes. A, B Changes in mouse body weight. C , D Glucose tolerance testing. E , F Insulin tolerance testing. G , H Estrous cycle evaluation via vaginal smears in mice (D, diestrus; P, proestrus; E, estrus; M, metestrus). I HE staining of mouse ovaries, Scale bar = 100 μm. Data are presented as Mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: Dehydroepiandrosterone (DHEA) and metformin were obtained from MedChemExpress (Shanghai, China).

Techniques: Staining

Journal: Journal of Ovarian Research

Article Title: Atractylenolide III mitigates polycystic ovary syndrome by activating FDX1-mediated proliferation of ovarian granulocyte cells via PI3K/AKT/mTOR

doi: 10.1186/s13048-025-01941-7

Figure Lengend Snippet: ATL-III increased FDX1 and PCNA expressions in DHEA-induced PCOS mice. A Western blot analysis of FDX1 ( B ) and PCNA ( D )expression levels in mouse ovarian tissue. C Immunohistochemistry (IHC) of FDX1 protein expression ( E ) in ovarian granulosa cells of mouse. F IHC of PCNA protein expression ( G ) in ovarian granulosa cells of mouse. Data are presented as Mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: Dehydroepiandrosterone (DHEA) and metformin were obtained from MedChemExpress (Shanghai, China).

Techniques: Western Blot, Expressing, Immunohistochemistry

Journal: Journal of Ovarian Research

Article Title: Atractylenolide III mitigates polycystic ovary syndrome by activating FDX1-mediated proliferation of ovarian granulocyte cells via PI3K/AKT/mTOR

doi: 10.1186/s13048-025-01941-7

Figure Lengend Snippet: The effect of ATL-III on FDX1 protein expression and cell proliferation in KGN cells. A , B Representative bands and statistical analysis of FDX1 protein expression in KGN cells treated with different concentrations of DHEA, n = 3. C - E Western blot analysis of the relative protein expression levels of FDX1 and PCNA after ATL-III treatment. F - G CCK-8 assay assessing the influence of ATL-III on the growth viability of KGN cells. H-I EdU assay examining the effect of ATL-III on KGN cell proliferation, Scale bar = 200 μm. Data are presented as Mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: Dehydroepiandrosterone (DHEA) and metformin were obtained from MedChemExpress (Shanghai, China).

Techniques: Expressing, Western Blot, CCK-8 Assay, EdU Assay

Journal: Journal of Ovarian Research

Article Title: Atractylenolide III mitigates polycystic ovary syndrome by activating FDX1-mediated proliferation of ovarian granulocyte cells via PI3K/AKT/mTOR

doi: 10.1186/s13048-025-01941-7

Figure Lengend Snippet: The effects of ATL-III on PI3K/AKT/mTOR pathway in ovarian granulocyte cells of mice and KGN cells. A Representative western blotting bands and quantitation of expression of AKT/p-AKT( B ), PI3K/p-PI3K ( C ), and mTOR/p-mTOR( D ) pathway in ovarian tissues of mice, n = 3. E Representative western blotting bands and quantitation of expression of PI3K/p-PI3K( F ), AKT/p-AKT( G ), and mTOR/p-mTOR( H ) pathway in KGN cells pretreated with DHEA, n = 3. Results are presented as Mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: Dehydroepiandrosterone (DHEA) and metformin were obtained from MedChemExpress (Shanghai, China).

Techniques: Western Blot, Quantitation Assay, Expressing